2020
Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions.
Wei BM, Hanlon D, Khalil D, Han P, Tatsuno K, Sobolev O, Edelson RL. Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions. The Yale Journal Of Biology And Medicine 2020, 93: 145-159. PMID: 32226344, PMCID: PMC7087063.Peer-Reviewed Original ResearchConceptsDendritic cellsExtracorporeal photopheresisDC maturationProfessional antigen-presenting cellsAntigen-specific immunityAntigen-presenting cellsImmunological capabilitiesAutoimmune disordersCancer immunotherapyLymphoid tissueImmune systemImmunotherapyInfectious diseasesPoor survivabilityTherapeutic endsPoor availabilityMaturationMultiple strategiesPhotopheresisCellsCancerPhotochemotherapyDiseaseImmunity
2019
Extracorporeal photochemotherapy induces bona fide immunogenic cell death
Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, Rivera-Molina F, Arshad N, Edelson RL, Galluzzi L. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death & Disease 2019, 10: 578. PMID: 31371700, PMCID: PMC6675789, DOI: 10.1038/s41419-019-1819-3.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine TriphosphateAnimalsAntigens, NeoplasmApoptosisCD8-Positive T-LymphocytesCell DifferentiationCell Line, TumorCell SurvivalDendritic CellsHMGB1 ProteinHumansImmunogenic Cell DeathLeukocytesLymphoma, T-Cell, CutaneousMethoxsalenMiceMonocytesPhotopheresisPhotosensitizing AgentsReceptor, Interferon alpha-betaUltraviolet RaysConceptsHigh mobility group box 1Tumor-associated antigensCutaneous T-cell lymphomaWhite blood cellsDendritic cellsImmunostimulatory signalsI interferonBona fide immunogenic cell deathMobility group box 1Such dendritic cellsSyngeneic immunocompetent miceCancer cellsT-cell lymphomaType I IFN receptorGroup box 1Immunogenic cell deathI IFN receptorATP-degrading enzymeSecretion of ATPMelanoma cell viabilityCognate immunityUVA irradiationAnticancer immunityImmunocompetent miceCalreticulin exposureNovel Protocol for Generating Physiologic Immunogenic Dendritic Cells.
Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 PMID: 31157760, DOI: 10.3791/59370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaDendritic cellsCellular vaccinesClinical efficacyAnti-tumor T cell immunityVivo anti-tumor responsesMonocyte-derived dendritic cellsTumor cellsSyngeneic mouse tumor modelsImmunogenic dendritic cellsAnti-cancer immunityT cell immunityAnti-tumor responseHuman dendritic cellsT-cell lymphomaAnti-tumor effectsKey mechanistic driversApoptotic tumor cellsMouse tumor modelsCell immunitySafety profileCancer immunotherapyCell lymphomaMouse modelBlood samples
2016
Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells
Kibbi N, Sobolev O, Girardi M, Edelson RL. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells. Transfusion And Apheresis Science 2016, 55: 146-152. PMID: 27317354, DOI: 10.1016/j.transci.2016.06.001.Peer-Reviewed Original ResearchConceptsCD8 T cell responsesCutaneous T-cell lymphomaT cell responsesCell responsesCD8 T cell populationsMonocyte-derived DCsAnti-tumor immunityT cell populationsT-cell lymphomaAntigen presenting cellsClass I major histocompatibilityCentral mechanistic roleMelanoma-associated proteinImmunotherapeutic managementHost diseaseAllograft rejectionPresenting cellsDendritic antigenImmunologic reactionsCell lymphomaMalignant cloneMajor histocompatibilityPathogenic clonesCell populationsAntigen